In people with obesity, taking both apitegromab and tirzepatide preserved 54.9% more lean mass than taking tirzepatide alone.
See the scientific wording
Combining the myostatin inhibitor apitegromab with the dual GLP-1/GIP agonist tirzepatide preserved 54.9% more lean mass compared to tirzepatide alone in patients with obesity.
Correlational — new studies may shift this
One low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Narrative ReviewReview2025
A summary of research says that a study found that adding a muscle-preserving drug to a weight-loss drug helped people keep 54.9% more muscle, which is exactly what the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Your body naturally makes a protein called myostatin that tells your muscles not to grow too big. The drug apitegromab blocks myostatin, so your muscles get the signal to grow instead of shrink. When you take a weight-loss drug like tirzepatide that makes you lose fat, your muscles might also shrink, but apitegromab stops that by keeping muscle-building pathways active.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In people with obesity, taking both apitegromab and tirzepatide preserved 54.9% more lean mass than taking tirzepatide alone.
Mechanism
1 studyYour body makes myostatin, which stops muscles from growing. Apitegromab blocks myostatin, so your muscles get the green light to grow. When you lose weight with tirzepatide, your body might burn muscle for energy, but apitegromab protects your muscle by keeping the growth signal on.
Your body naturally makes a protein called myostatin that tells your muscles not to grow too big. The drug apitegromab blocks myostatin, so your muscles get the signal to grow instead of shrink. When you take a weight-loss drug like tirzepatide that makes you lose fat, your muscles might also shrink, but apitegromab stops that by keeping muscle-building pathways active.
Myostatin binds to activin type II receptors (ActRIIA/B) on skeletal muscle cells, recruiting type I receptors (ALK4/5) which phosphorylate SMAD2/3.
Phosphorylated SMAD2/3 forms a complex with SMAD4, translocates to the nucleus, and represses genes that drive myoblast proliferation, differentiation, and fusion, thereby limiting muscle growth.
Apitegromab binds to myostatin, preventing its interaction with ActRIIA/B. This blocks SMAD2/3 phosphorylation and downstream repression of myogenesis.
Removal of SMAD2/3-mediated repression allows myoblast proliferation, differentiation, and fusion, increasing muscle protein synthesis and leading to muscle hypertrophy. During a caloric deficit induced by tirzepatide, this anabolic signal preserves lean mass that would otherwise be lost.
Evidence from Studies
Supporting (1)
Community contributions welcome
A summary of research says that a study found that adding a muscle-preserving drug to a weight-loss drug helped people keep 54.9% more muscle, which is exactly what the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Myostatin Inhibitors Combined with GLP-1 Agonists for Lean Mass Preservation in Obesity
Systematic review and meta-analysis of randomized controlled trials comparing myostatin inhibitor plus GLP-1/GIP agonist vs GLP-1/GIP agonist alone in adults with obesity, with lean mass change as primary outcome, followed for at least 6 months.
Double-Blind RCT of Apitegromab Plus Tirzepatide vs Tirzepatide Alone for Lean Mass in Obesity
Double-blind, placebo-controlled randomized trial in adults with obesity (BMI ≥30), comparing apitegromab + tirzepatide vs tirzepatide + placebo, with lean mass by DXA at baseline and 12 months, and adverse event monitoring.
Prospective Cohort Study of Body Composition Changes with Combination Therapy in Obesity
Prospective cohort study of patients with obesity receiving apitegromab + tirzepatide vs tirzepatide alone in routine clinical practice, with lean mass measured by DXA or BIA at baseline and annually for 3 years, controlling for confounders.
Case-Control Study of Lean Mass Preservation in Patients on Combination vs Monotherapy
Nested case-control study within a cohort of patients on tirzepatide, comparing those who added apitegromab (cases) vs those who did not (controls), matched on age, sex, BMI, and baseline lean mass, with lean mass change as outcome.